Exhibit 99.2 THE IMMUNE RESPONSE CORPORATION SECURITIES PURCHASE AGREEMENT DATED AS OF FEBRUARY 9, 2006 WITH RESPECT TO 8% SECURED CONVERTIBLE PROMISSORY NOTE AND WARRANT SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the...Securities Purchase Agreement • August 11th, 2006 • Qubit Holdings LLC • Biological products, (no disgnostic substances) • New York
Exhibit 99.1 AGREEMENT RELATING TO THE FILING OF A JOINT STATEMENT As required by Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, the undersigned agree that this Schedule 13G, dated January 10, 2006, relating to the Common Stock, par...Joint Statement Agreement • January 25th, 2006 • Qubit Holdings LLC • Pharmaceutical preparations
As required by Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, the undersigned agree that this Schedule 13G, dated January 10, 2006, relating to the Common Stock, par value $0.01, of Vyteris Holdings (Nevada), Inc., shall be filed on behalf of the undersigned.
Exhibit 99.1 AGREEMENTSchedule 13d • August 11th, 2006 • Qubit Holdings LLC • Biological products, (no disgnostic substances)
The undersigned agree that this Schedule 13D, dated as of the date hereof, relating to the Common Stock, par value $0.0025 per share, of The Immune Response Corporation, shall be filed on behalf of the undersigned.
Exhibit 99.3 THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF (THE "CONVERSION SHARES") HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THESE SECURITIES MAY NOT BE OFFERED OR SOLD EXCEPT...Convertible Promissory Note • August 11th, 2006 • Qubit Holdings LLC • Biological products, (no disgnostic substances)
